Xbiotech Inc. (XBIT) Files Form 4 Insider Selling : Queena Han Sells 427 Shares

Xbiotech Inc. (XBIT): Queena Han , VP Finance & HR of Xbiotech Inc. sold 427 shares on Sep 8, 2016. The Insider selling transaction was reported by the company on Sep 12, 2016 to the Securities and Exchange Commission. The shares were sold at $15.00 per share for a total value of $6,405.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 26, 2016, W Thorpe Mckenzie (director 10% owner) purchased 20,000 shares at $13.96 per share price.On Dec 23, 2015, Queena Han (VP Finance / HR) sold 30,000 shares at $10.51 per share price.Also, On Nov 19, 2015, Michael Stecher (Medical Director) sold 1,800 shares at $14.00 per share price.

XBiotech Inc: On Monday, Sep 12, 2016 heightened volatility was witnessed in XBiotech Inc which led to swings in the share price. The shares opened for trading at $13.85 and hit $14.4699 on the upside , eventually ending the session at $14.28, with a gain of 3.25% or 0.45 points. The heightened volatility saw the trading volume jump to 94,256 shares. The 52-week high of the share price is $25 and the company has a market cap of $463 M . The 52-week low of the share price is at $6.36.

XBiotech Inc Money Flow Index Chart

Company has been under the radar of several Street Analysts.XBiotech Inc is Reiterated by Noble Financial to Buy and the brokerage firm has raised the Price Target to $ 30 from a previous price target of $24 .The Rating was issued on Jun 28, 2016.

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Humanmonoclonal antibodies for treating various diseases. The Company focuses to develop MABp1 a therapeutic antibody which specifically neutralizes interleukin-1 alpha (IL-1a). IL-1a is a pro-inflammatory protein produced by leukocytes and other cells where it plays arole in inflammation. The Company has completed a Phase I/II clinical trials for MABp1 (Xilonix) as a treatment for cancer at MD Anderson Cancer Center. The Company is also involved in investigating MABp1 in clinical trials for other indicationsincluding vascular disease type II diabetes acne and psoriasis. The Company has begun using its True Human antibody technology for developing a therapy for Ebola virus infection.

Leave a Reply

XBiotech Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on XBiotech Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.